journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/29146159/a-patient-with-malignant-pleural-mesothelioma-carrying-braf-v600e-mutation-responding-to-vemurafenib
#1
LETTER
Yao Chen, Baisong Chen, Xiaolian Zhu, Jianping Zhong
No abstract text is available yet for this article.
November 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29126573/lipoid-pneumonia-mimicking-multifocal-lung-cancer-in-a-patient-with-a-remote-laryngectomy-and-a-recently-diagnosed-lung-cancer-pet-ct-findings
#2
LETTER
Luis Gorospe, Raquel García-Latorre, Odile Ajuria-Illarramendi, Paola Arrieta, Rosa María Gómez-García, Gemma María Muñoz-Molina, María Eugenia Olmedo-García
No abstract text is available yet for this article.
November 7, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29126574/incidental-retroperitoneal-malignant-solitary-fibrous-tumor-detected-at-lung-cancer-screening-with-low-dose-thoracic-ct
#3
LETTER
Luis Gorospe, Joaquín Carlos Sánchez-Monforte, Jacobo Cabañas-Montero, Paola Arrieta, Vital Hevia-Palacios, María Eugenia Reguero-Callejas, Isabel García-Gómez-Muriel
No abstract text is available yet for this article.
November 6, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29096978/treatment-of-a-nsclc-patient-with-osimertinib-based-on-the-detection-of-the-egfr-t790m-resistance-mutation-in-cerebrospinal-fluid
#4
LETTER
Sandrine Théoleyre, Ingrid Masson, Guillaume Herbreteau, Audrey Vallée, Hélène Sénellart, Marc G Denis
No abstract text is available yet for this article.
October 28, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110857/inter-relationship-between-pd-l1-expression-and-clinic-pathological-features-and-driver-gene-mutations-in-pulmonary-sarcomatoid-carcinomas
#5
Filippo Lococo, Federica Torricelli, Giulio Rossi, Marco Alifano, Diane Damotte, Cristian Rapicetta, Ione Tamagnini, Alberto Cavazza, Simonetta Piana, Carla Galeone, Massimiliano Paci, Alessia Ciarrocchi
INTRODUCTION: Pulmonary Sarcomatoid Carcinoma (PSC) is a rare subset of NSCLC, associated with worse prognosis and resistant to platinum-based regimens. Recent investigations have shown high levels of PD-L1 expression in PSC, providing a rationale for the potential use of immunotherapy. In this study, we investigated whether the PD-L1 expression was related to clinico-pathologic and molecular characteristics. MATERIALS AND METHODS: Fortythree surgically-resected PSCs were selected from 2006 to 2014 and clinical information retrieved...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110856/external-validation-of-prognostic-indices-for-overall-survival-of-malignant-pleural-mesothelioma
#6
Yuki Kataoka, Yosuke Yamamoto, Taiichiro Otsuki, Sawako Kaku, Nobuko Maehashi-Wada, Shingo Fukuma, Masataka Hirabayashi, Takashi Nakano, Shunichi Fukuhara
OBJECTIVE: There are several prognostic indices (PIs) to predict overall survival (OS) in malignant pleural mesothelioma (MPM) patients. Before using a clinical prediction model in the actual clinical setting, empiric evaluation of its performance based on datasets that were not used to develop the model (i.e., external validation) is essential. The purpose of this study was to conduct an external validation of the PIs for MPM. MATERIALS AND METHODS: A retrospective cohort study was performed on MPM patients treated at 2 tertiary hospitals in Japan between 2007 and 2015...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110855/predictors-for-chemotherapy-in-early-stage-small-cell-lung-carcinoma-sclc-a-national-cancer-database-ncdb-analysis
#7
LETTER
Zaheer Ahmed, Punita Grover, Kevin F Kennedy, Ashiq Masood, J Russell Davis, Janakiraman Subramanian
No abstract text is available yet for this article.
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110854/sorafenib-and-continued-erlotinib-or-sorafenib-alone-in-patients-with-advanced-non-small-cell-lung-cancer-progressing-on-erlotinib-a-randomized-phase-ii-study-of-the-sarah-cannon-research-institute-scri
#8
David R Spigel, Mark S Rubin, Victor G Gian, Dianna L Shipley, Howard A Burris, Rebecca A Kosloff, Kent C Shih, Raven Quinn, F Anthony Greco, John D Hainsworth
PURPOSE: To evaluate the efficacy of erlotinib, continued after tumor progression, plus sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung cancer (NSCLC) who previously benefitted from single-agent erlotinib. PATIENTS AND METHODS: Patients with progressive refractory NSCLC who had previously benefitted from erlotinib (objective response or stable disease >8weeks) were randomized to receive treatment with either erlotinib and sorafenib (400mg orally twice daily) or sorafenib alone...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110853/cd44-variant-dependent-regulation-of-redox-balance-in-egfr-mutation-positive-non-small-cell-lung-cancer-a-target-for-treatment
#9
Yuko Kawano, Eiji Iwama, Kenji Tsuchihashi, Daisuke Shibahara, Taishi Harada, Kentaro Tanaka, Osamu Nagano, Hideyuki Saya, Yoichi Nakanishi, Isamu Okamoto
OBJECTIVES: The regulation of redox balance in cancer cells is an important factor in tumor development and chemoresistance, with oncogene activation having been shown to induce the generation of reactive oxygen species (ROS). Activating mutations of the epidermal growth factor receptor gene (EGFR) are oncogenic drivers in non-small cell lung cancer (NSCLC), but it has remained unknown whether ligand-independent EGFR signaling conferred by EGFR mutation triggers ROS generation in NSCLC cells...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110852/radiological-classification-of-multiple-lung-cancers-and-the-prognostic-impact-based-on-the-presence-of-a-ground-glass-opacity-component-on-thin-section-computed-tomography
#10
Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
OBJECTIVES: Revised TNM classification has proposed a new clinical classification of lung cancers with multiple pulmonary sites. However, definition of the radiological findings and their prognostic impacts are still controversial. Therefore, we evaluated the prognostic impact of multiple lung cancers based on the radiologic classifications concluded from findings on thin-section computed tomography. METHODS: Among surgically resected 1440 c-stage I lung cancer patients, 246 (17...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110851/acquired-resistance-to-crizotinib-in-advanced-lung-adenocarcinoma-with-met-exon-14-skipping
#11
LETTER
Yu Zhang, Jinping Yin, Feng Peng
No abstract text is available yet for this article.
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110850/nanoparticle-targeted-folate-receptor-1-enhanced-photodynamic-therapy-for-lung-cancer
#12
Tatsuya Kato, Cheng S Jin, Hideki Ujiie, Daiyoon Lee, Kosuke Fujino, Hironobu Wada, Hsin-Pei Hu, Robert A Weersink, Juan Chen, Mitsuhito Kaji, Kichizo Kaga, Yoshiro Matsui, Brian C Wilson, Gang Zheng, Kazuhiro Yasufuku
OBJECTIVE: Despite modest improvements, the prognosis of lung cancer patients has still remained poor and new treatment are urgently needed. Photodynamic therapy (PDT), the use of light-activated compounds (photosensitizers) is a treatment option but its use has been restricted to central airway lesions. Here, we report the use of novel porphyrin-lipid nanoparticles (porphysomes) targeted to folate receptor 1 (FOLR1) to enhance the efficacy and specificity of PDT that may translate into a minimally-invasive intervention for peripheral lung cancer and metastatic lymph nodes of advanced lung cancer...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110849/continued-use-of-afatinib-with-the-addition-of-cetuximab-after-progression-on-afatinib-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-and-acquired-resistance-to-gefitinib-or-erlotinib
#13
Leora Horn, Scott Gettinger, D Ross Camidge, Egbert F Smit, Yelena Y Janjigian, Vincent A Miller, William Pao, Matthias Freiwald, Jean Fan, Bushi Wang, Vikram K Chand, Harry J M Groen
OBJECTIVES: In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired resistance to erlotinib or gefitinib. Here, a separate cohort exploring afatinib plus cetuximab after progression on afatinib is reported. MATERIALS AND METHODS: Patients with EGFR mutation-positive NSCLC who progressed on erlotinib or gefitinib received afatinib 40mg daily until progression, followed by afatinib daily plus cetuximab 500mg/m(2) every 2 weeks until progression or intolerable adverse events (AEs)...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110848/relationship-between-nodule-count-and-lung-cancer-probability-in-baseline-ct-lung-cancer-screening-the-nelson-study
#14
Marjolein A Heuvelmans, Joan E Walter, Robin B Peters, Geertruida H de Bock, Uraujh Yousaf-Khan, Carlijn M van der Aalst, Harry J M Groen, Kristiaan Nackaerts, Peter Ma van Ooijen, Harry J de Koning, Matthijs Oudkerk, Rozemarijn Vliegenthart
OBJECTIVES: To explore the relationship between nodule count and lung cancer probability in baseline low-dose CT lung cancer screening. MATERIALS AND METHODS: Included were participants from the NELSON trial with at least one baseline nodule (3392 participants [45% of screen-group], 7258 nodules). We determined nodule count per participant. Malignancy was confirmed by histology. Nodules not diagnosed as screen-detected or interval cancer until the end of the fourth screening round were regarded as benign...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110847/symptomatic-pseudo-progression-followed-by-significant-treatment-response-in-two-lung-cancer-patients-treated-with-immunotherapy
#15
Maximilian J Hochmair, Sophia Schwab, Otto C Burghuber, Dagmar Krenbek, Helmut Prosch
In the setting of pseudo-progression in a cancer patient who receives immunotherapeutic treatment, discontinuation of therapy is recommended if the patient is symptomatic. Here, we present two patients with advanced adenocarcinoma of the lung who developed massive tumor growth after initiation of treatment with the anti-PD-1 antibody pembrolizumab. Even though clinical deterioration occurred in the form of severe dyspnea and weight loss, pembrolizumab therapy was continued, as the speed of tumor growth suggested pseudo-progression and the tumors showed marked PD-L1 expression...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110846/egfr-mutation-prevalence-in-asia-pacific-and-russian-patients-with-advanced-nsclc-of-adenocarcinoma-and-non-adenocarcinoma-histology-the-ignite-study
#16
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Nicola Normanno, Laksmi Wulandari, Konstantin Laktionov, Achmad Hudoyo, Yong He, Yi-Ping Zhang, Meng-Zhao Wang, Chien Ying Liu, Marianne Ratcliffe, Rose McCormack, Martin Reck
OBJECTIVES: Limited understanding exists of epidermal growth factor receptor (EGFR) mutation frequency in less common subgroups of advanced non-small-cell lung cancer (aNSCLC) (e.g. squamous cell carcinoma [SCC]), and to what extent local practices exclude patients from EGFR testing based on their clinical characteristics. MATERIALS AND METHODS: IGNITE (non-comparative/-interventional; NCT01788163) was conducted in 90 centres (Asia-Pacific/Russia). Eligible patients: local/metastatic aNSCLC; chemotherapy-naïve, newly-diagnosed/recurrent disease after resection; ineligible for curative treatment...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110845/an-international-epidemiological-analysis-of-young-patients-with-non-small-cell-lung-cancer-adujov-clicap
#17
Luis Corrales-Rodríguez, Oscar Arrieta, Luis Mas, Renata Báez-Saldaña, Omar Castillo-Fernández, Normand Blais, Claudio Martín, Melissa Juárez, Priyanka Khanna, Allan Ramos-Esquivel, Ludwing Bacon, Leonardo Rojas, Beatriz Wills, George Oblitas, María Angelina Pérez, Mauricio Cuello, Andrés Felipe Cardona
BACKGROUND: A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies have documented and analyzed epidemiological characteristics of this population. MATERIALS AND METHODS: We performed an international epidemiological analysis of 389 young patients with NSCLC. Data was collected from centers participating in the Latin American Consortium for Lung Cancer Research (AduJov-CLICaP)...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110844/genetic-polymorphisms-and-lung-cancer-risk-evidence-from-meta-analyses-and-genome-wide-association-studies
#18
REVIEW
Caiyang Liu, Huijie Cui, Dongqing Gu, Min Zhang, Yanfei Fang, Siyu Chen, Mingshuang Tang, Ben Zhang, Huanwen Chen
A growing number of studies investigating the association between Single Nucleotide Polymorphisms (SNPs) and lung cancer risk have been published since over a decade ago. An updated integrative assessment on the credibility and strength of the associations is required. We searched PubMed, Medline, and Web of Science on or before August 29(th), 2016. A total of 198 articles were deemed eligible for inclusion, which addressed the associations between 108 variants and lung cancer. Among the 108 variants, 63 were reported to be significantly associated with lung cancer while the remaining 45 were reported non-significant...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110843/frequency-and-clinical-impact-of-preoperative-circulating-tumor-cells-in-resectable-non-metastatic-lung-adenocarcinomas
#19
Nadia Dandachi, Verena Tiran, Joerg Lindenmann, Luka Brcic, Nicole Fink-Neuboeck, Karl Kashofer, Gudrun Absenger, Angelika Bezan, Richard J Cote, Ram Datar, Marija Balic
OBJECTIVES: Despite successful surgery, 30-50% of patients with resectable non-small cell lung cancer develop tumor recurrence within 5 years of surgery. MATERIALS AND METHODS: In this prospective study, we performed CTC enumerations in 40 patients with non-metastatic lung adenocarcinoma (NMLA) using a size-based microfilter. Additionally, cfDNA isolated from plasma was analyzed in 35 out of 40 patients. RESULTS: CTCs were identified in 15 out of 40 patients (37...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29110842/patient-reported-outcome-measures-proms-in-the-management-of-lung-cancer-a-systematic-review
#20
REVIEW
Youssef Ben Bouazza, Ibrahim Chiairi, Ouiam El Kharbouchi, Lesley De Backer, Greetje Vanhoutte, Annelies Janssens, Jan P Van Meerbeeck
Lung cancer is often associated with a poor quality of life, as reflected by patient-reported outcome measures (PROMs). The aim of this paper is to describe and compare the PROMs that are available. In this manuscript, we review the impact of PROMs on the management of lung cancer. Quality of the study and risk of bias were assessed using the appraisal tools recommended by the Dutch Cochrane Center. Out of 51 studies included in this review, ten instruments were identified and categorized as either generic, cancer- or lung cancer-specific...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"